About
EPICS Therapeutics is a clinical-stage biotechnology company developing small-molecule inhibitors targeting RNA epigenetic regulation, with its lead program EP102, a METTL3 inhibitor, currently in clinical evaluation for solid tumors including NSCLC, pancreatic, ovarian, and colorectal cancers.
Explore EPICS Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.